Orient Biotech(SH:688298) Sou Hu Cai Jing·2025-07-27 21:01Summary of Key Points Core Viewpoint - The company, Zhejiang Oriental Gene Biological Products Co., Ltd., is actively engaging in a share buyback program to maintain its value and protect shareholder interests, with a planned expenditure of between 25 million to 50 million RMB [1]. Trading Information - As of July 25, 2025, the company's stock closed at 29.39 RMB, down 0.64%, with a turnover rate of 2.41% and a trading volume of 48,600 shares, resulting in a total transaction amount of 142 million RMB [1]. - On the same day, the net outflow of funds from major investors was 9.49 million RMB, accounting for 6.67% of the total transaction amount, while retail investors saw a net inflow of 10.96 million RMB, representing 7.7% of the total transaction amount [1][3]. Company Announcements - The company announced a share buyback plan on June 26, 2025, with the buyback period set from June 26, 2025, to September 25, 2025. The buyback aims to acquire shares worth between 25 million to 50 million RMB [1]. - As of July 25, 2025, the company has repurchased 9,555 shares through the Shanghai Stock Exchange, which is 0.0047% of the total share capital of 20,160,000 shares, at a price range of 29.20 to 29.25 RMB per share, totaling 279,336 RMB [1].